Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported net product revenue of approximately $13.5 million for the second quarter of 2026, a significant increase from $2 million in the same period last year. This growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. During the quarter, TONMYA recorded 12,592 total prescriptions, reflecting a 100% sequential increase. New patient prescriptions rose by 36%, while refills surged by 207%, indicating strong uptake and patient adherence.
The commercial performance of TONMYA is underpinned by broad payer coverage. Currently, the drug has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. This expansion is likely to further boost sales and solidify TONMYA's market position in the fibromyalgia treatment landscape, which has seen limited innovation for over 15 years.
Beyond commercial achievements, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). This study represents a strategic expansion of the company's CNS franchise, potentially addressing a significant unmet medical need. Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. This program highlights Tonix's commitment to addressing infectious diseases through its immunology platform.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that these resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides the company with the flexibility to execute its strategic priorities, including advancing its pipeline and supporting TONMYA's commercial growth.
The positive financial results and pipeline progress underscore Tonix's transformation into a fully-integrated, commercial-stage biotechnology company. With TONMYA's successful launch and a robust pipeline targeting CNS and immunology indications, Tonix is well-positioned to create long-term value for shareholders. For more details on the full press release, visit https://ibn.fm/6Yytj.
For the latest news and updates on Tonix Pharmaceuticals, refer to the company's newsroom at https://ibn.fm/TNXP.
